KORRO BIO INC
KRRONASDAQ🏆 #3904 by market capUS Equity
$688.83▲ $3.65 (+0.53%)
Simulated priceTrack KRRO
Get earnings, price moves & breaking news on Telegram
24h▲ 0.5%
7d▲ 6914.6%
14d▲ 4871.7%
30d▲ 5459.6%
ytd▲ 8488.9%
1y▲ 1343.2%
🏦Market Cap
$141M
Small Cap
📈Revenue Growth (YoY)
-62.1%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
22.3x
Expensive
Otter Score
64
Fair
Trading Snapshot
- Day Range
- $678.46 – $691.60
- 52-Week Range
- $5.20 – $55.89
- Volume
- $2.24B
- Avg Volume
- $2.20B
- Shares Outstanding
- 14.4M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- 22.3x
- EPS (TTM)
- $-10.00
- Dividend Yield
- —
- Dilution (1yr)
- +5.3%
Why Investors Own KRRO
- ✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 32% gross margin and 7% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
KORRO BIO INC
KRROFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▲ +181.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
33.0%▼ −67.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$87M▼ −5.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$79M▲ +1.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.4M▲ +5.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$22M▼ −$33M YoY
StockOtter · stockotter.spaceAbout KORRO BIO INC
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100
Analyst Price Target
ⓘAverage Target
$891.87
▲ +29.5% Upside
High Target$966.75
Low Target$736.16
Based on 33 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
KORRO BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift KRRO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
KORRO BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.